Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

F Kronenberg, S Mora, ESG Stroes… - European heart …, 2022 - academic.oup.com
Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta …

P Hu, KI Dharmayat, CAT Stevens, MTA Sharabiani… - Circulation, 2020 - Am Heart Assoc
Background: Contemporary studies suggest that familial hypercholesterolemia (FH) is more
frequent than previously reported and increasingly recognized as affecting individuals of all …

Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects

SO Beheshti, CM Madsen, A Varbo… - Journal of the American …, 2020 - jacc.org
Background Despite the greater prevalence of familial hypercholesterolemia (FH) in
subjects with ischemic heart disease (IHD), premature IHD, and severe …

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …

J Knuuti, W Wijns, A Saraste, D Capodanno… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Heart disease and stroke statistics—2019 update: a report from the American Heart Association

EJ Benjamin, P Muntner, A Alonso, MS Bittencourt… - Circulation, 2019 - Am Heart Assoc
Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …

[HTML][HTML] Inclisiran for the treatment of heterozygous familial hypercholesterolemia

FJ Raal, D Kallend, KK Ray, T Turner… - … England Journal of …, 2020 - Mass Medical Soc
Background Familial hypercholesterolemia is characterized by an elevated level of low-
density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic …

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

AV Khera, M Chaffin, KG Aragam, ME Haas, C Roselli… - Nature …, 2018 - nature.com
A key public health need is to identify individuals at high risk for a given disease to enable
enhanced screening or preventive therapies. Because most common diseases have a …

Heart disease and stroke statistics—2018 update: a report from the American Heart Association

EJ Benjamin, SS Virani, CW Callaway… - circulation, 2018 - Am Heart Assoc
Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Lipid and lipoprotein metabolism

KR Feingold - Endocrinology and Metabolism Clinics, 2022 - endo.theclinics.com
Lipids are insoluble in water and therefore cholesterol and triglycerides need to be
transported in association with proteins (ie, lipoproteins) in the bloodstream. Lipoproteins …